icon-folder.gif   Conference Reports for NATAP  
 
  5th IAS Conference on HIV Pathogenesis, Treatment and Prevention
July 19th-22nd 2009
Capetown, South Africa
Back grey_arrow_rt.gif
 
 
 
Reyataz Studies at IAS
 
 
  ARIES Study
 
written by Jules Levin
 
Patients switched at week 36 from boosted Reyataz+ Epzicom (abacavir+3TC) to unboosted Reyataz and retained Epzicom. After 48 weeks on the unboosted Reyataz at week 84 of the study the 2 regimens were non-inferior, 86% <50 for unboosted vs 81% for boosted Reyataz (ITT-E, TLOVR) but the lipids profile was better for unboosted Reyataz. Look at the last slide in the attached report to see week 84 lipids. Hyperbilirubinemia decreased more in the unboosted arm (from 14% to 4%) compared to the boosted arm (from 12% to 10%) from week 36 to 84. For the patients with >100,000 c/ml at baseline unboosted had 87% <50 and for the boosted arm 82% had <50. For the patients with <100,000 c/l at baseline 85% in the unboosted & 79% in the boosted had <50 c/ml.
 
The GSK press release said: From weeks 36-84, significantly greater decreases in total cholesterol (-14, 6 mg/dL; P<0.0001), triglycerides (-34, -4 mg/dL; P<0.0001) and total cholesterol/HDL ratio (-0.34, 0; P=0.0004) were observed in patients in the ritonavir-sparing arm compared to those in the continuation arm, respectively. The decrease in total bilirubin from week 36 to week 84 was significantly larger in the ritonavir-sparing arm compared to the continuation arm (P<0.0001).
 
Efficacy and Safety of Atazanavir/RTV vs. Lopinavir/RTV in Treatment-Na´ve Patients with Advanced Disease: CASTLE Study 96-Week Results - (07/29/09)
 
Reyataz Induction/Maintenance From Boosted to Unboosted: Similar Efficacy and Tolerability of Atazanavir (ATV) Compared to Atazanavir/Ritonavir (ATV/r), each with Abacavir/Lamivudine (ABC/3TC) after Initial Suppression with ABC/3TC + ATV/r: 84 Week Results of the ARIES Trial - (07/22/09)
 
EPZICOM + atazanavir regimen provided comparable efficacy to EPZICOM + atazanavir/ritonavir regimen in treatment-naive HIV-infected patients - press release - (07/22/09)
 
New Drugs, New strategies - IAS Report on Treatment for Naives- (08/12/09) Joe Eron MD
 
Atazanavir Effective After Atazanavir/Ritonavir Induction in Naive Patients - written by Mark Mascolini - (07/22/09)
 
The Safety, Efficacy, and Steady State Pharmacokinetics of Atazanavir/Ritonavir (ATV/r) Once Daily During Pregnancy: Results of Study AI424182 - (07/30/09)
 
Efficacy, safety and tolerability of dual therapy with raltegravir 400mg bid and atazanavir 200mg bid in antiretroviral experienced patients. - (08/04/09) US studies of this nuke-sparing regimen will use different Reyataz dosing.